

P&T Committee Meeting Minutes

Subject:	- spar whent of fleatti
	Medicaid Pharmaceutical and Therapeutic Committee Meeting
Location:	628 North Fourth Street
	Baton Rouge, LA
	Bienville Building
	Room 118
Date:	May 4, 2018
Members Present:	■ Dr. Brian Boulmay
	■ Dr. Christopher Blais
	■ Dr. Brandt Harold
	■ Dr. Jill Comeau
	■ Dr. Tammy Hart
	■ Dr. James Hussey
	■ Dr. Edward Mader
	■ Dr. Catherine McDonald
	■ Senator Fred Mills, RPh
	■ Ben Orlando, RPh
	 Representative Roger Pope
	■ Marty R. McKay, RPh
DHH Pharmacy	■ Melwyn Wendt, RPh
Program Staff	 Germaine Becks-Moody, PhD, BHSF Program Manager
Present:	■ Sue Fontenot, RPh
	■ Paul Knecht, RPh
	 Kim Sullivan
	 Mary Wolf
Contractors Present:	 Nina Bandali, PharmD, Magellan Medicaid Administration
	 Hind Douiki, PharmD, Magellan Medicaid Administration



	 Mark Lacour, Certified Court Reporter
Others Present:	Presenters are listed in the minutes and sign in sheets and others in attendance from DHH, Bureau of Health Services Financing, Pharmacy Benefits Section upon request.

Call to Order

Marty R. McKay, Chairman, called the meeting to order at 10:10 a.m.

Parliamentary Business

- A. Introduction of Members/Roll Call. Committee members and staff introduced themselves.
- B. Introduction of LDH & Magellan Staff. LDH and Magellan staff introduced themselves.
- C. Additional agenda items. Mr. McKay asked if there were any requests for additional agenda items. There was a request to add 2-C on the agenda. After a roll call vote, the item was added to the agenda.
- D. Announcement of election of officers. Senator Mills nominated Mr. McKay for Chair and Mr. Orlando seconded it. Mr. McKay was elected chairman by unanimous vote.
 Senator Mills nominated Mr. Orlando for co-chair and Dr. Mader seconded it. Mr. Orlando was elected co-chairman by unanimous vote.
- **E. Approval of Minutes.** Mr. McKay asked for a motion to approve the minutes from November 2, 2016. There were no objections to approving the minutes.
- F. Attendance/Additional Meetings. Dr. Wendt suggested having dates in mind for additional meetings. She apologized for possibly overstepping the committee members to have quorum. She expressed appreciation for the members participation because the P&T meetings affect the supplemental rebates for fee-for-service.

Dr. Wendt stated that the department is currently working with 5 MCOs and with senator Mills to move to a single PDL. If the single PDL takes place, then the 5 MCOs will follow the recommendations of the department in terms of preferred and prior authorized drugs. She hopes the single PDL will be executed and the goal of the department will be to make things simpler for prescribers, pharmacy providers, and recipients. She reminded the members that the provided packet includes the Louisiana Medicaid Preferred Drug List overview.

Senator Mills stated that the legislation is working on streamlining the process and reducing the committee members number. He indicated that the most important aspect with the single PDL is whether it is cost effective.

Representative Pope echoed senator Mills' comments and expressed his support for senator Mills' work.

P&T Committee Overview

A. P & T Background

Ms. Sullivan reminded everyone that the committee was established by state statute in 2001 and, as senator Mills indicated, there is some legislation pending that is going to make minor changes. The committee is advisory to the secretary of the department who looks at the recommendations and she accepts or rejects



them. The committee is also free to make recommendations on any areas of the pharmacy program to the secretary.

B. P & T Bylaws

Ms. Sullivan informed the members that the committee has some bylaws which they should have and can read at their leisure. The bylaws follow the statutes closely.

Ethics Reminder

Ms. Sullivan reminded all that P&T Committee members are subject to the Governmental Code of Ethics. She strongly recommended, especially to new committee members, to go to the Board of Ethics website to familiarize themselves with the requirements of the board and the required restrictions. If anyone has personal ethical questions or issues, she can be emailed or called. Ms. Sullivan added that committee members do not have to complete the 45-minute training.

New Business

A. Explanation of TOP\$, Monographs and Cost Sheets

Dr. Bandali provided an overview of the TOP\$ supplemental rebate pool that Louisiana Medicaid participates in. She indicated to the members that they should have received clinical documents, in the form of Therapeutic Class Reviews or New Drug Updates. They should also have cost sheets which include relative values, instead of actual numbers, in order to comply with the privacy laws regarding rebates.

B. Therapeutic Class Reviews of Spring Drug Classes/Drug Manufacturer Testimony

In accordance with state law and the P&T Committee's bylaws, the following provided public testimony or answered questions raised by the Committee during the Committee's review.

Presenter	Representing	Drug/Issue
Bobby Greely	Biogen	Tecfidera
Smitty Burner	Alkermes	Vivitrol
Valerie Ink	Indivior	Sublocade

Analgesics Narcotics, Long

Dr. Comeau made the motion to amend the recommendation. Mr. Orlando seconded the motion. After discussion, there was no objection to the motion.

- Fentanyl transderm
- Morphine ER tablet
- Embeda



Analgesics Narcotics, Short

Mr. Orlando made the motion to accept. Dr. McDonald seconded the motion. There was no objection to the motion.

Committee recommendations for the PDL are:

- Apap/Codeine elixir, tablet
- Hydrocodone/apap solution/tablet
- Hydromorphone tablet
- Morphine IR tablet
- Oxycodone/apap tablet
- Oxycodone tablet
- Tramadol
- Tramadol/apap

Androgenic Agents - New

Mr. Orlando made the motion to accept. Dr. Blais seconded the motion. There was no objection to the motion.

Committee recommendations for the PDL are:

- AndrogeL Gel Packet (Transderm.)
- Androgel Gel Pump (Transderm.)

Angiotensin Modulator Combinations

Mr. Orlando made the motion to accept. Senator Mills seconded the motion. There was no objection to the motion.

- Amlodipine/benazepril
- Amlodipine/valsartan
- Amlodipine/valsartan/HCTZ



Angiotensin Modulators

Dr. Blais made the motion to accept. Mr. Orlando seconded the motion. There was no objection to the motion. Committee recommendations for the PDL are:

- Benazepril
- Enalapril
- Enalapril/HCTZ
- Entresto
- Irbesartan
- Irbesartan/HCTZ
- Lisinopril
- Lisinopril/HCTZ
- Losartan
- Losartan/HCTZ
- Ramipril
- Valsartan
- Valsartan/HCTZ

Antibiotics, GI

Mr. Orlando made the motion to accept. Dr. Comeau seconded the motion. There was no objection to the motion.

- Metronidazole tablet
- Neomycin
- Vancomycin capsule



Antibiotics, Inhaled

Mr. Orlando made the motion to accept. Dr. McDonald seconded the motion. There was no objection to the motion.

Committee recommendations for the PDL are:

- Bethkis
- Kitabis Pak

Antibiotics, Topical

Dr. Comeau made the motion to accept. Mr. McKay seconded the motion. There was no objection to the

Committee recommendations for the PDL are:

Mupirocin ointment

Antibiotics, Vaginal

Mr. Orlando made the motion to accept. Dr. McDonald seconded the motion. There was no objection to the motion.

Committee recommendations for the PDL are:

- Clindamycin
- Metronidazole

Anticoagulants

Mr. Orlando made the motion to accept. Dr. McDonald seconded the motion. There was no objection to the motion.

- Eliquis
- Eliquis Dose pack
- Enoxaparin Syringe



- Fragmin vial
- Lovenox vial
- Pradaxa
- Warfarin
- Xarelto
- Xarelto dose pack

Antivertigo/Antiemetic Agents

Mr. Orlando made the motion to accept. Dr. McDonald seconded the motion. There was no objection to the motion.

Committee recommendations for the PDL are:

- Emend
- Meclizine
- Metoclopramide solution, tablet, vial
- Ondansetron ODT, solution, tablets, vial
- Prochlorperazine oral
- Promethazine ampule, rectal, syrup, tablet, vial
- Transderm-scop

Antifungals, Oral

Dr. McDonald made the motion to accept. Mr. Orlando seconded the motion. There was no objection to the motion.



- Clotrimazole mucous membrane
- Fluconazole suspension, tablet
- Griseofulvin suspension
- Nystatin suspension, tablet
- Terbinafine

Antifungals, Topical

Dr. Blais made the motion to accept. Mr. Orlando seconded the motion. There was no objection to the motion. Committee recommendations for the PDL are:

- Clotrimazole cream, solution Rx
- Clotrimazole-betamethasone cream
- Ketoconazole cream, shampoo
- Nystatin cream, ointment, powder

Antimigraine Agents, Triptans

Mr. Orlando made the motion to accept. Dr. Blais seconded the motion. There was no objection to the motion.

Committee recommendations for the PDL are:

- Imitrex nasal
- Rizatriptan ODT, tablet
- Sumatriptan tablet, vial
- · Zolmitriptan tablet, ODT

Antiparasitics, Topical

Mr. Orlando made the motion to accept. Dr. MacDonald seconded the motion. There was no objection to the motion.



- Natroba
- Permethrin cream
- Sklice

Antivirals, Oral

Mr. Orlando made the motion to accept. Dr. Comeau seconded the motion. After discussion, there was no objection to the motion.

Committee recommendations for the PDL are:

- Acyclovir capsule, tablet
- Famciclovir
- Relenza
- Rimantadine
- Tamiflu capsule, suspension
- Valacyclovir
- Zovirax suspension

Antivirals, Topical

Mr. Orlando made the motion to accept. Dr. Blais seconded the motion. There was no objection to the motion.

Committee recommendations for the PDL are:

Zovirax cream

Beta Blockers

Dr. Comeau made the motion to accept. Mr. Orlando seconded the motion. There was no objection to the motion.



- Atenolol
- Atenolol/chlorthalidone
- Bisoprolol HCTZ
- Bystolic
- Carvedilol
- Labetalol
- Metoprolol
- Metroprolol XL
- Propranolol ER
- Propranolol solution, tablet
- Sotalol

Bladder Relaxant Preparations

Mr. Orlando made the motion to accept. Dr. McDonald seconded the motion. There was no objection to the motion.

Committee recommendations for the PDL are:

- Oxybutynin ER
- Oxybutynin syrup, tablet
- Toviaz
- Vesicare

Bone Resorption Suppression and Related Agents

Mr. Orlando made the motion to accept. Dr. Brandt seconded the motion. There was no objection to the motion.

- Alendronate tablet
- Calcitonin salmon nasal



BPH Treatments

Dr. McDonald made the motion to accept. Mr. Orlando seconded the motion. There was no objection to the motion.

Committee recommendations for the PDL are:

- Alfuzosin
- Doxazosin
- Dutasteride
- Finasteride
- Tamsulosin
- Terazosin

Calcium Channel Blockers

Mr. Orlando made the motion to accept. Dr. Comeau seconded the motion. There was no objection to the motion.

Committee recommendations for the PDL are:

- Amlodipine
- Diltiazem capsule ER
- Diltiazem tablet
- Nifedipine ER
- Verapamil tablet
- Verapamil tablet ER

Cephalosporins and Related Antibiotics

Mr. Orlando made the motion to keep cephalexin suspension preferred. Dr. Comeau seconded the motion. After discussion and unanimous vote, there was no objection to the motion.



- Amoxicillin/clavulanate suspension, tablets
- Cefadroxil capsule
- Cefdinir capsule, suspension
- Cefprozil suspension, tablet
- Cefuroxime tablet
- Cephalexin capsule, suspension
- Suprax capsule, chew tablet

Fluoroquinolones

Dr. Blais made the motion to accept. Dr. McDonald seconded the motion. There was no objection to the motion.

Committee recommendations for the PDL are:

- Ciprofloxacin tablet
- Levofloxacin tablet

GI Motility, Chronic

Mr. Orlando made the motion to accept. Dr. McDonald seconded the motion. There was no objection to the

Committee recommendations for the PDL are:

- Amitiza
- Linzess
- Movantik

Growth Hormone

Dr. McDonald made the motion to accept. Dr. Blais seconded the motion. There was no objection to the motion.

- Norditropin pen
- Nutropin AQ pen



H. Pylori Treatment

Mr. Orlando made the motion to accept. Dr. Blais seconded the motion. There was no objection to the motion.

Committee recommendations for the PDL are:

Pylera

Hepatitis C Agents

Mr. Orlando made the motion to accept. Dr. McDonald seconded the motion. After discussion, there was no

Committee recommendations for the PDL are:

- **Epclusa**
- Mavyret
- Pegasys Proclick
- Pegasys Syringe
- Pegasys Vial
- Ribavirin tablet

Hypoglycemics, Alpha-Glucosidase Inhibitors - New

Mr. Orlando made the motion to accept. Senator Mills seconded the motion. There was no objection to the motion.

Committee recommendations for the PDL are:

Acarbose

Hypoglycemics, Incretin Mimetics/Enhancers

Representative Pope made the motion to accept. Mr. Orlando seconded the motion. There was no objection to the motion.

- Bydureon pen, vial
- Byetta pen
- Glyxambi



- Janumet
- Janumet XR
- Januvia
- Jentadueto
- Tradjenta
- Victoza

Hypoglycemics, Insulin and Related Agents

Mr. Orlando made the motion to accept. Dr. Comeau seconded the motion. There was no objection to the motion.

Committee recommendations for the PDL are:

- Apidra Solostar Pen, vial
- Humalog Junior Kwikpen
- Humalog pen, vial
- Humalog mix pen, mix vial
- Humulin 500 u/mL vial
- Humulin 70/30 vial OTC
- Humulin Pen OTC
- Humulin vial OTC
- · Lantus Solostar pen, vial
- Levemir pens, vial
- Novolog cartridge, pen, vial

Hypoglycemics, Meglitinides

Mr. Orlando made the motion to accept. Dr. Brandt seconded the motion. There was no objection to the motion.



- Nateglinide
- Repaglinide

Hypoglycemics, Metformins - New

Mr. Orlando made the motion to accept. Dr. McDonald seconded the motion. There was no objection to the motion.

Committee recommendations for the PDL are:

- Glipizide-metformin
- Glyburide-metformin
- Metformin
- Metformin ER (Glucophage XR)

Hypoglycemics, SGLT2

Mr. Orlando made the motion to accept. Dr. McDonald seconded the motion. There was no objection to the motion.

Committee recommendations for the PDL are:

- Invokamet
- Invokana
- Farxiga
- Jardiance

Hypoglycemics, Sulfonylureas

Mr. Orlando made the motion to accept. Dr. Blais seconded the motion. There was no objection to the motion.



- Glimepiride
- Glipizide
- Glipizide ER
- Glyburide
- Glyburide micronized

Hypoglycemics, TZD

Mr. Orlando made the motion to accept. Dr. Blais seconded the motion. There was no objection to the motion.

Committee recommendations for the PDL are:

Pioglitazone

Immunosuppressives, Oral

Mr. Orlando made the motion to accept. Dr. McDonald seconded the motion. There was no objection to the motion.

Committee recommendations for the PDL are:

- Azathioprine
- Cyclosporine, modified capsule
- Mycophenolate mofetil capsule, tablet
- Sirolimus (AG)
- Tacrolimus

Lincosamides/Oxazolidinones/Streptogramins

Representative Pope made the motion to accept. Mr. Orlando seconded the motion. There was no objection to the motion.

- Clindamycin capsule
- Clindamycin palmitate solution
- Linezolid tablet, suspension



Lipotropics, Other

Mr. Orlando made the motion to accept. Dr. Blais seconded the motion. There was no objection to the motion.

Committee recommendations for the PDL are:

- Cholestyramine/aspartame
- Cholestyramine/sucrose
- Colestipol tablet
- Fenofibrate tablet (generic Tricor)
- Gemfibrozil
- Niacin ER
- Niacor
- Omega-3 Acid Ethyl Esters

Lipotropics, Statins

Senator Mills made the motion to accept. Representative Pope seconded the motion. There was no objection to the motion.

Committee recommendations for the PDL are:

- Atorvastatin
- Lovastatin
- Pravastatin
- Rosuvastatin
- Simvastatin

Macrolides/Ketolides

Mr. Orlando made the motion to accept. Senator Mills seconded the motion. There was no objection to the motion.



- Azithromycin packet, suspension, tablet
- Clarithromycin tablet
- Eryped 400 suspension
- Ery-Tab
- Erythromycin Base Capsule DR

Multiple Sclerosis Agents

Mr. Orlando made the motion to accept. Dr. McDonald seconded the motion. After discussion, there was no objection to the motion.

Committee recommendations for the PDL are:

- Avonex pen, vial
- Betaseron Kit
- Copaxone 20 mg/mL
- Gilenya
- Rebif injection, Rebidose

Nitrofuran Derivatives - New

Mr. Orlando made the motion to accept. Dr. Blais seconded the motion. There was no objection to the motion.

Committee recommendations for the PDL are:

- Nitrofurantoin macrocrystals capsule
- Nitrofurantoin mono-macro capsule

Opiate Dependence Treatments

Mr. Orlando made the motion to accept. Dr. McDonald seconded the motion. After discussion, there was no objection to the motion.

- Naloxone syringe, vial
- Naltrexone
- Narcan spray



Suboxone film

PAH Agents, Oral and Inhaled

Mr. Orlando made the motion to accept. Dr. McDonald seconded the motion. There was no objection to the motion.

Committee recommendations for the PDL are:

- Letairis
- Sildenafil
- Tracleer

Pancreatic Enzymes

Mr. Orlando made the motion to accept. Dr. McDonald seconded the motion. There was no objection to the

Committee recommendations for the PDL are:

- Creon
- Zenpep

Phosphate Binders

Mr. Orlando made the motion to accept. Dr. Blais seconded the motion. There was no objection to the motion.

Committee recommendations for the PDL are:

- Calcium acetate capsule
- Renagel

Pituitary Suppressive Agents, LHRH

Dr. Boulmay made the motion to accept. Mr. Orlando seconded the motion. There was no objection to the motion.

Committee recommendations for the PDL are:

- Lupron depot, depot kit
- Lupron depot-ped, depot-ped kit

Platelet Aggregation Inhibitors

Mr. Orlando made the motion to accept. Dr. Hart seconded the motion. After discussion, there was no objection to the motion.



Committee recommendations for the PDL are:

- Aggrenox
- Brilinta
- Clopidogrel
- Dipyridamole

Proton Pump Inhibitors

Mr. Orlando made the motion to accept. Dr. McDonald seconded the motion. There was no objection to the motion.

Committee recommendations for the PDL are:

- Omeprazole
- Pantoprazole
- Protonix suspension

Skeletal Muscle Relaxants

Senator Mills made the motion to accept. Representative Pope seconded the motion. There was no objection to the motion.

Committee recommendations for the PDL are:

- Baclofen
- Chlorzoxazone
- Cyclobenzaprine
- Methocarbamol
- Tizanidine tablet

Tetracyclines

Dr. McDonald made the motion to accept. Senator Mills seconded the motion. Mr. Orlando had an objection to make tetracycline non-preferred; Dr. Comeau seconded it.



- Doxycycline hyclate capsule, tablet
- Doxycycline monohydrate 50 mg and 100 mg capsule
- Minocycline capsule

Ulcerative Colitis Agents

Representative Pope made the motion to accept. Mr. Orlando seconded the motion. There was no objection to the motion.

Committee recommendations for the PDL are:

- Apriso
- Balsalazide
- Canasa
- Sulfasalazine
- Sulfasalazine DR

Vasodilators, Coronary

Mr. Orlando made the motion to accept. Senator Mills seconded the motion. There was no objection to the motion.

Committee recommendations for the PDL are:

- Isosorbide dinitrate
- Isosorbide mononitrate
- Isosorbide mononitrate SR
- Nitro-Bid ointment
- Nitroglycerin transdermal, sublingual

Single Drugs

The new drug reviews or single drug reviews are regarding products that have come to the market since the last review of the class.

In accordance with state law and the P&T Committee's bylaws, the following provided public testimony or answered questions raised by the Committee during the Committee's review.



Presenter	Representing	
hannon Mann		Drug/Issue
8.653336	Sunovion	Lonhala Magnair
ucy Dicharry	Pfizer	The Ividgilali
NOTE: Names of speakers		Eucrisa
ingle de	who were present and yielded thei	r time back were not cap

The single drugs were reviewed and a recommendation was made. P&T Committee recommendations follow:

Alzheimer's Agents

Mr. Orlando made the motion to accept. Senator Mills seconded the motion. There was no objection to the motion.

Committee recommendations for the PDL are:

Non-prefer Namzaric Dose Pack

Antihistamines, minimally Sedating

Mr. Orlando made the motion to accept the recommendations. Dr. Brandt seconded the motion. There was no objection to the motion.

Committee recommendations for the PDL are:

- Non-prefer loratadine capsule OTC
- Non-prefer Xyzal solution OTC
- Non-prefer Xyzal tablet OTC

Antihyperuricemics

Mr. Orlando made the motion to accept. Dr. Comeau seconded the motion. There was no objection to the motion.

Committee recommendations for the PDL are:

Non-prefer Duzallo

Antiparkinson's Agents

Senator Mills made the motion to accept. Representative Pope seconded the motion. There was no objection to the motion.

- Non-prefer Gocovri
- Non-prefer Rasagiline
- Non-prefer Xadago



Antipsychotics

Mr. Orlando made the motion to accept. Dr. McDonald seconded the motion. There was no objection to the motion.

Committee recommendations for the PDL are:

- Non-prefer Seroquel XR
- Prefer Quetiapine ER

Bronchodilators, Beta Agonist

Senator Mills made the motion to accept. Mr. Orlando seconded the motion. There was no objection to the motion.

Committee recommendations for the PDL are:

Non-prefer Levalbuterol HFA

COPD Agents

Mr. Orlando made the motion to accept. Dr. McDonald seconded the motion. There was no objection to the motion.

Committee recommendations for the PDL are:

Non-prefer Lonhala Magnair

Cytokine and CAM Antagonists

Mr. Orlando made the motion to accept. Dr. Brandt seconded the motion. There was no objection to the motion.

Committee recommendations for the PDL are:

- Non-prefer Enbrel Cartridge
- Non-prefer Inflectra vial
- Non-prefer Kevzara
- Non-prefer Renflexis
- Non-prefer Siliq
- Non-prefer Tremfya

Emollients

Mr. Orlando made the motion to accept. Senator Mills seconded the motion. There was no objection to the motion.



Committee recommendations for the PDL are:

Non-prefer Dexeryl

Epinephrine, Self-Injected

Mr. Orlando made the motion to accept. Dr. Brandt seconded the motion. There was no objection to the motion.

Committee recommendations for the PDL are:

- Non-prefer EpiPen Jr
- Non-prefer EpiPen
- Prefer Epinephrine 0.15 MG (generic Epipen Jr)
- Prefer Epinephrine 0.3 MG (generic Epipen)

Glucocorticoids, Inhaled

Senator Mills made the motion to accept. Representative Pope seconded the motion. There was no objection to the motion.

Committee recommendations for the PDL are:

- Non-prefer QVAR Redihaler
- Non-prefer Trelegy Ellipta
- Prefer Flovent HFA inhaler

Immunomodulators, Atopic Dermatitis

Mr. Orlando made the motion to accept. Senator Mills seconded the motion. There was no objection to the motion.

Committee recommendations for the PDL are:

- Non-prefer Dupixent
- Non-prefer Eucrisa

Intranasal Rhinitis Agents

Mr. Orlando made the motion to accept. Senator Mills seconded the motion. There was no objection to the motion.

Committee recommendations for the PDL are:

Non-prefer Sinuva sinus implant

Leukotriene Modifiers

Mr. Orlando made the motion to accept. Dr. Blais seconded the motion. There was no objection to the motion.



Non-prefer Zileuton ER

Neuropathic Pain

Mr. Orlando made the motion to accept. Dr. Comeau seconded the motion. There was no objection to the motion.

Committee recommendations for the PDL are:

Non-prefer Lyrica CR

NSAIDs

Senator Mills made the motion to accept. Representative Pope seconded the motion. There was no objection to the motion.

Committee recommendations for the PDL are:

Non-prefer Diclofenac/Capsicum Oleoresin Kit

Ophthalmic Antibiotics

Mr. Orlando made the motion to accept. Dr. Blais seconded the motion. There was no objection to the motion.

Committee recommendations for the PDL are:

Non-prefer Moxifloxacin (generic Vigamox)

Ophthalmics for Allergic Conjunctivitis

Mr. Orlando made the motion to accept. Dr. McDonald seconded the motion. There was no objection to the motion.

Committee recommendations for the PDL are:

Non-prefer Olopatadine drops (generic Pataday)

Ophthalmics, Anti-Inflammatories

Mr. Orlando made the motion to accept. Senator Mills seconded the motion. There was no objection to the motion.

Committee recommendations for the PDL are:

Non-prefer Bromsite

Ophthalmics, Anti-Inflammatory/Immunomodulator

Mr. Orlando made the motion to accept. Dr. Comeau seconded the motion. There was no objection to the motion.



Committee recommendations for the PDL are:

Prefer Restasis Multidose

Ophthalmics, Glaucoma Agents

Mr. Orlando made the motion to accept. Senator Mills seconded the motion. There was no objection to the motion.

Committee recommendations for the PDL are:

- Non-prefer Timolol (generic Istalol)
- Non-prefer Vyzulta

Progestational Agents

Dr. Brandt made the motion to accept. Mr. Orlando seconded the motion. There was no objection to the motion.

Committee recommendations for the PDL are:

Prefer Makena Auto Injector

Steroids, Topical High

Mr. Orlando made the motion to accept. Senator Mills seconded the motion. There was no objection to the motion.

Committee recommendations for the PDL are:

Non-prefer Ellzia

Steroids, Topical Low

Mr. Orlando made the motion to accept. Senator Mills seconded the motion. There was no objection to the motion.

Committee recommendations for the PDL are:

Non-prefer Micort-HC

Steroids, Topical Medium

Mr. Orlando made the motion to accept. Dr. Comeau seconded the motion. There was no objection to the motion.



Committee recommendations for the PDL are:

- Non-prefer Flurandrenolide Lotion
- Non-prefer Flurandrenolide Ointment

Stimulants and Related Agents

Mr. Orlando made the motion to accept. Dr. Blais seconded the motion. There was no objection to the motion.

Committee recommendations for the PDL are:

- Non-prefer Adzenys ER Suspension
- Non-prefer Cotempla XR ODT
- Non-prefer Mydayis ER
- Non-prefer Strattera
- Prefer Atomoxetine
- Prefer Vyvanse Chewable Tablet

Other Business

Dr. Wendt informed the committee that, in their packet, there is a PDL list which includes the supplemental rebate amounts. She discussed the initiatives that the department is implementing in order to address the opioid epidemic. Dr. Wendt thanked the committee members who made it to the meeting. Mr. McKay also expressed his thanks for their prompt attention.

Proposed Therapeutic Classes to be Reviewed at Next Meeting

Therapy classes to be reviewed for the November 2018 meeting will be posted on the DHH Medicaid Pharmacy and Therapeutics Committee page as "Agenda."

Next Meeting Date

The next committee meeting is scheduled for October 26, 2018 or November 2, 2018.

Adjournment

The meeting adjourned at 1:45 p.m.

Chairman, P&T Committee

